tiprankstipranks
Finch Therapeutics appoints Matthew Blischak CEO
PremiumThe FlyFinch Therapeutics appoints Matthew Blischak CEO
2y ago
Finch enters CP101 clinical trial agreement with Brigham and Women’s Hospital
Premium
The Fly
Finch enters CP101 clinical trial agreement with Brigham and Women’s Hospital
2y ago
Finch Therapeutics price target lowered to $7 from $17 at H.C. Wainwright
Premium
The Fly
Finch Therapeutics price target lowered to $7 from $17 at H.C. Wainwright
2y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100